One study found that the expressing CD19 (which included a positive result or a partial positive result in at least one blast population in cases with MPAL in children) benefited from ALL-type therapy, and the 5-year event-free survival (EFS) rate was 83% ± 5.3%, while the 5-year EFS rate of AML and mixed-type (blending elements of AML and ALL regimens) therapy was 0% ± 0% and 28% ± 14%, respectively (both p < 0.0001) (18). This evidence concerns the gene CD19 and acute myeloid leukemia.